ReviewInternational immunopharmacology2023
Lung fibrosis: Post-COVID-19 complications and evidences.
Review in International immunopharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- Supplementation of αKG along with TGFβ/HIF1α antagonist rescues lung fibrosis in mice with severe SARS-CoV-2 infection.Journal of translational medicine · 2026Article
- Impact of COVID-19 vaccination on radiation-induced lung injury in breast cancer patients: a retrospective cohort study.Discover oncology · 2026Article
- Geospatial and temporal trends of interstitial lung disease subtypes and KL-6 biomarker in China: a nationwide study (2016-2024).Respiratory research · 2026Article
- Monitoring the Adverse Implications of Coronavirus 2019-induced Pulmonary Complications on Patients' Respiratory Capacity and Physical Abilities with Moderate and Severe Signs during Interval Follow-up.Journal of medical signals and sensors · 2026Article
- Integrated Serum Pharmacochemistry, Network Pharmacology, and Transcriptomics Reveal the Mechanisms and Active Constituents of Qingfei Huoxue Decoction Against Bleomycin-Induced Pulmonary Fibrosis.Drug design, development and therapy · 2026Article
- Research Progress on Anti-fibrotic Effects and Mechanisms of Tetrandrine.Chinese journal of integrative medicine · 2025Review
- MicroRNAs in long COVID: roles, diagnostic biomarker potential and detection.Human genomics · 2025Review
- Diagnosis of invasive pulmonary aspergillosis using metagenomic next-generation sequencing and conventional microbial tests post-COVID-19 pandemic.Microbiology spectrum · 2025Article
- Advancing the Identification of Bioactive Molecules and the Construction of a Synergistic Drug Delivery System in Combating Lung Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Recent advances in TAM mechanisms in lung diseases.Journal of translational medicine · 2025Review
- Long COVID and Associated Factors Among Chinese Residents Aged 16 Years and Older in Canada: A Cross-Sectional Online Study.Biomedicines · 2025Article
- Impact of immunosuppressive therapy on pulmonary perfusion in kidney transplant recipients after COVID-19 illness.Frontiers in medicine · 2025Article
- Retrospective cohort analysis on predicting pulmonary fibrosis in elderly SARS-CoV-2-infected patients.Frontiers in cellular and infection microbiology · 2025Article
- The development of a therapeutic strategy for post-acute sequelae of COVID-19 should be based on an efficient classification of pathogenesis.Frontiers in medicine · 2025Article
- Overlapping Systemic Proteins in COVID-19 and Lung Fibrosis Associated with Tissue Remodeling and Inflammation.Biomedicines · 2024Article
- Discovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approach.Acta pharmaceutica Sinica. B · 2024Article
- Rehabilitative interventions in patients with persistent post COVID-19 symptoms-a review of recent advances and future perspectives.European archives of psychiatry and clinical neuroscience · 2024Review
- The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19.Cell communication and signaling : CCS · 2024Review
- The Role of Dental-derived Stem Cell-based Therapy and Their Derived Extracellular Vesicles in Post-COVID-19 Syndrome-induced Tissue Damage.Stem cell reviews and reports · 2024Review
- Longer ICU stay and invasive mechanical ventilation accelerate telomere shortening in COVID-19 patients 1 year after recovery.Critical care (London, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCOVID 19, a lethal viral outbreak that devastated lives and the economy across the globe witnessed non-compensable respiratory illnesses in patients. As been evaluated in reports, patients receiving long-term treatment are more prone to acquire Pulmonary Fibrosis (PF). Repetitive damage and repair of alveolar tissues increase oxidative stress, inflammation and elevated production of fibrotic proteins ultimately disrupting normal lung physiology skewing the balance towards the fibrotic milieu.
aimIn the present work, we have discussed several important pathways which are involved in post-COVID PF. Further, we have also highlighted the rationale for the use of antifibrotic agents for post-COVID PF to decrease the burden and improve pulmonary functions in COVID-19 patients.
conclusionBased on the available literature and recent incidences, it is crucial to monitor COVID-19 patients over a period of time to rule out the possibility of residual effects. There is a need for concrete evidence to deeply understand the mechanisms responsible for PF in COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.